Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Diabetes Obesity and Metabolism

Topics

Medicine

Pathology

Internal Medicine

Endocrinology

Urology

Show all topics

DOI

10.1111/dom.12189